596 Development of Processes and Products for Pharmaceuticals and Hybrid Therapeutics


Description:
The session will include presentations that describe tools, technologies and applications related to the development of pharmaceutical products. Applications in both small molecules and biopharmaceuticals are welcome.

Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Co-Sponsor(s):
Pharmaceuticals (15B)


Chair:
Michael L. Hoffman
Abbvie Laboratories
100 Abbott Park Road
Abbott Park, IL
60064-3500
Email: Michael.Hoffman@abbvie.com

Co-Chair:
Christopher L. Burcham
Senior Engineering Research Advisor
Eli Lilly & Company
Indianapolis, IN
46285
Email: cburcham@lilly.com


Papers:
596a
Engineering Considerations for Dissolved Oxygen Sensor Response Across Silicone Membranes in 3-L Single Use Bioreactors
William Tran, Merck & Co.; John Bowers, Merck & Co.; T. Craig Seamans, Merck & Co.
596b
Process Development Tool to Rapidly Predict the Stability of Biopharmaceuticals
Sarah Hedberg, Imperial College London; Yolanda Hutabarat, Imperial College London; Jerry Heng, Imperial College London; Jonathan Haigh, Fujifilm Diosynth Biotechnologies; Daryl Williams, Imperial College London
596c
Model-Based Process Optimization for Upstream Bioreactor Production–Downstream Chromatographic Separation of CHO Cell Monoclonal Antibodies (mAb)
Uroš Novak, Chemical Institute; Drejc Kopač, National Institute of Chemistry Slovenia; Miša Cajnko, Chemical Institute; Andrej Pohar, National Institute of Chemistry; Matic Grom, Chemical Institute; Blaž Likozar, National Institute of Chemistry Slovenia
596d
Exploring the Multi-Minima Behavior of Organic Crystal Polymorphs at Finite-Temperature
Eric Dybeck, University of Virginia; Michael Shirts, University of Colorado Boulder
596e
Iterative Synthesis of Heteropolymers Using Organic Solvent Nanofiltration
Ruiyi Liu, Imperial College London; Piers Gaffney, Imperial College London; Patrizia Marchetti, Imperial College London; Marc Schaepertoens, Imperial College London; Ruijiao Dong, Imperial College London; Andrew G. Livingston, Imperial College London
596f
Challenges in Process Development of Antibody Drug Conjugates (ADCs)
Vimalkumar Patel, Pfizer Inc
596g
Improved Manufacturing Process for Semi-Synthetic Calicheamicin Linker-Payload En Route to Antibody-Drug Conjugates
Leo J. Letendre, Pfizer, Inc.; Frank W. Kotch, Pfizer, Inc.; Amarnauth Prashad, Pfizer, Inc.; Vimalkumar Patel, Pfizer Inc; Wesley Swanson, Pfizer, Inc.; Xi Hu, Pfizer, Inc.; Lawrence Chen, Pfizer, Inc.; April Xu, Pfizer, Inc.; Sen Zhang, Pfizer, Inc.; Stephen Freese, Pfizer, Inc.; Eric Bortell, Pfizer, Inc
Abstract Submissions Closed
See more of this Group/Topical: Pharmaceutical Discovery, Development and Manufacturing Forum
<< Previous Session | Next Session >>